Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Corneal matrix repair therapy with the regenerating agent in neurotrophic persistent epithelial defects.

Literature DB >> 29259918

Corneal matrix repair therapy with the regenerating agent in neurotrophic persistent epithelial defects.

Canan Asli Utine¹, Ceren Engin Durmaz¹, Nilufer Koçak¹.

Abstract

Year: 2017 PMID： 29259918 PMCID： PMC5733527 DOI： 10.18240/ijo.2017.12.25

Source DB: PubMed Journal: Int J Ophthalmol ISSN： 2222-3959 Impact factor: 1.779

× No keyword cloud information.

21 in total

Review 1. Neurotrophic keratitis.

Authors: S Bonini; P Rama; D Olzi; A Lambiase
Journal: Eye (Lond) Date: 2003-11 Impact factor: 3.775

2. Regenerating matrix-based therapy for chronic wound healing: a prospective within-subject pilot study.

Authors: Suzanne L Groah; Alexander Libin; Miriam Spungen; Kim-Loan Nguyen; Earthaleen Woods; Marjan Nabili; Jessica Ramella-Roman; Denis Barritault
Journal: Int Wound J Date: 2010-11-16 Impact factor: 3.315

Review 3. [Regenerating agents (RGTAs): a new therapeutic approach].

Authors: D Barritault; J-P Caruelle
Journal: Ann Pharm Fr Date: 2006-03

4. [Management of herpes zoster neurotrophic ulcer using a new matrix therapy agent (RGTA): A case report].

Authors: I De Monchy; A Labbé; N Pogorzalek; G Gendron; M M'Garrech; G Kaswin; M Labetoulle
Journal: J Fr Ophtalmol Date: 2011-10-19 Impact factor: 0.818

5. RGTA-based matrix therapy in severe experimental corneal lesions: safety and efficacy studies.

Authors: F Brignole-Baudouin; J M Warnet; D Barritault; C Baudouin
Journal: J Fr Ophtalmol Date: 2013-08-16 Impact factor: 0.818

6. Effect of the Regenerative Agent Poly(Carboxymethylglucose Sulfate) on Corneal Wound Healing After Corneal Cross-Linking for Keratoconus.

Authors: George D Kymionis; Dimitrios A Liakopoulos; Michael A Grentzelos; Konstantinos I Tsoulnaras; Efstathios T Detorakis; Béatrice Cochener; Miltiadis K Tsilimbaris
Journal: Cornea Date: 2015-08 Impact factor: 2.651

7. The healing of alkali-injured cornea is stimulated by a novel matrix regenerating agent (RGTA, CACICOL20): a biopolymer mimicking heparan sulfates reducing proteolytic, oxidative and nitrosative damage.

Authors: Jitka Cejkova; Celine Olmiere; Cestmir Cejka; Peter Trosan; Vladimir Holan
Journal: Histol Histopathol Date: 2013-10-09 Impact factor: 2.303

8. [Pilot study of a new matrix therapy agent (RGTA OTR4120) in treatment-resistant corneal ulcers and corneal dystrophy].

Authors: C Khammari Chebbi; K Kichenin; N Amar; H Nourry; J M Warnet; D Barritault; C Baudouin
Journal: J Fr Ophtalmol Date: 2008-05 Impact factor: 0.818

Corneal matrix repair therapy with the regenerating agent in neurotrophic persistent epithelial defects.

Review 1. Neurotrophic keratitis.

2. Regenerating matrix-based therapy for chronic wound healing: a prospective within-subject pilot study.

Review 3. [Regenerating agents (RGTAs): a new therapeutic approach].

4. [Management of herpes zoster neurotrophic ulcer using a new matrix therapy agent (RGTA): A case report].

5. RGTA-based matrix therapy in severe experimental corneal lesions: safety and efficacy studies.

6. Effect of the Regenerative Agent Poly(Carboxymethylglucose Sulfate) on Corneal Wound Healing After Corneal Cross-Linking for Keratoconus.

7. The healing of alkali-injured cornea is stimulated by a novel matrix regenerating agent (RGTA, CACICOL20): a biopolymer mimicking heparan sulfates reducing proteolytic, oxidative and nitrosative damage.

8. [Pilot study of a new matrix therapy agent (RGTA OTR4120) in treatment-resistant corneal ulcers and corneal dystrophy].

9. Treatment of Acanthamoeba neurotrophic corneal ulcer with topical matrix therapy.

10. A Rapid Response to Matrix Therapy With RGTA in Severe Epidermolysis Bullosa.

Review 1. Persistent Corneal Epithelial Defects: A Review Article.

2. Case Reports for Topical Treatment of Corneal Ulcers with a New Matrix Therapy Agent or RGTA^® in Dogs.